EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Four challenges to CAR T cells breaking the glass ceiling

Stefanie R Bailey, Trisha R Berger, Charlotte Graham, Rebecca C Larson, Marcela V Maus

European Journal of Immunology · 2023-11 · 53 (11)

DOI: 10.1002/eji.202250039 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Immunology, online erschienen am 11.01.2023. Verfasst von Stefanie R Bailey und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA, USA. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Neoplasms. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 87 Literaturangaben. Gefördert von: NCI NIH HHS, NIGMS NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cell‐based therapies using chimeric antigen receptor T cells (CAR T) have had dramatic efficacy in the clinic and can even mediate curative responses in patients with hematologic malignancies. As living drugs, engineered cells can still be detected in some patients even years after the original infusion. The excitement around the cell therapy field continues to expand as recent reports have shown that CAR T cells can induce remission in patients with autoimmune disease. While these promising advances in the field garner hope for wide‐spread utility of CAR T therapies across diseases, several roadblocks exist that currently limit the access and efficacy of this therapy in the clinic. Herein, we will discuss four major obstacles that the CAR T field faces, including toxicity, identifying tumor‐specific antigens, improving function in solid tumors, and reducing manufacturing complexity and cost. CAR T cells have potential for a multitude of diseases, but these glass ceilings will need to be broken in order to improve clinical responses and make this potentially life‐saving therapy accessible to a larger patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenNeoplasmsHumansReceptors, Antigen, T-CellT-LymphocytesImmunotherapy, AdoptiveAntigens, NeoplasmTumor Microenvironment

Stichwörter der Autor:innen

CAR T cellsimmunotherapyresistance mechanismstoxicitytumor antigens

Substanzen

Receptors, Chimeric AntigenReceptors, Antigen, T-CellAntigens, Neoplasm

Autor:innen und Institutionen

  • Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA, USA.
  • Harvard Medical School, Boston, MA, USA.

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS
  • NIAID NIH HHS

Zitieren

APA

Bailey, S. R., Berger, T. R., Graham, C., Larson, R. C., & Maus, M. V. (2023). Four challenges to CAR T cells breaking the glass ceiling. European Journal of Immunology, 53(11). https://doi.org/10.1002/eji.202250039

Vancouver

Bailey SR, Berger TR, Graham C, Larson RC, Maus MV. Four challenges to CAR T cells breaking the glass ceiling. European Journal of Immunology. 2023;53(11). doi:10.1002/eji.202250039

BibTeX
@article{Bailey2023,
  author = {Bailey, Stefanie R and Berger, Trisha R and Graham, Charlotte and Larson, Rebecca C and Maus, Marcela V},
  title = {Four challenges to CAR T cells breaking the glass ceiling},
  journal = {European Journal of Immunology},
  year = {2023},
  volume = {53},
  number = {11},
  doi = {10.1002/eji.202250039}
}
Kostenlos starten →